Novavax stock up 9% as COVID-19 vaccine shows 90% overall efficacy

• Novavax (NASDAQ:NVAX) soars 9% premarket in reaction to the announcement that NVX-CoV2373, its recombinant protein-based COVID-19 vaccine met the primary endpoint in PREVENT-19 Phase 3 trial.
• NVX-CoV2373 demonstrated overall efficacy of 90.4% (95% CI: 82.9, 94.6), achieving its primary endpoint.
• The vaccine